Researchers have developed a quantitative lateral flow immunoassay for measuring soluble AXL in plasma as a potential aid to pancreatic ductal adenocarcinoma diagnosis.
Pancreatic ductal adenocarcinoma (PDAC) is commonly diagnosed after the disease has advanced. Imaging, tissue sampling, and histopathologic assessment remain central to diagnosis, while carbohydrate antigen 19-9 analysis is used mainly to support disease monitoring rather than population screening or definitive primary diagnosis.
Soluble AXL, or sAXL, is produced when the extracellular region of the AXL receptor tyrosine kinase is released through proteolytic cleavage. Previous ELISA studies found higher plasma sAXL concentrations in patients with PDAC than in healthy individuals or patients with chronic pancreatitis.
Núria Vázquez-Bellón and colleagues developed a colorimetric lateral flow immunoassay intended to transfer sAXL measurement from a laboratory ELISA format to a faster, more portable platform.
The assay used a monoclonal capture antibody and a biotinylated detection antibody. Anti-biotin gold nanoparticle conjugates generated the colorimetric signal. The researchers systematically assessed antibody concentrations, buffer composition, membrane type, and other assay conditions to improve signal intensity and reproducibility while reducing background.
Before constructing the lateral flow test, the team evaluated the selected immunoreagents in a sandwich ELISA. This laboratory assay produced a linear response for sAXL and reached a reported limit of detection of 0.16 ng/mL.
The lateral flow assay was then evaluated using plasma from a Barcelona-Hospital del Mar cohort comprising 20 patients with PDAC and 20 healthy controls. The test detected the higher sAXL concentrations associated with PDAC and statistically differentiated the patient and control groups. Lateral flow measurements were compared with ELISA findings, providing a reference for the new assay’s quantitative results.
The use of gold nanoparticles allows the strip to produce a visible signal with limited equipment, while quantitative interpretation provides more information than a simple positive or negative result. This format could eventually support testing closer to the patient or provide a rapid preliminary result before further laboratory and imaging investigations.
However, the study represents an early clinical evaluation rather than a validation for routine diagnosis. The cohort was small and included only healthy controls and patients with PDAC. It did not test the assay’s ability to distinguish PDAC from chronic pancreatitis, benign pancreatic disease, other cancers, or inflammatory conditions that may affect circulating sAXL.
The findings therefore do not establish the test as a screening assay or replacement for imaging, histopathology, cytology, or laboratory ELISA. Larger, independent and multicenter studies will be needed to establish reference intervals, clinical cutoffs, sensitivity, specificity, and performance across disease stages and relevant differential diagnoses.
